Glaab W E, Risinger J I, Umar A, Kunkel T A, Barrett J C, Tindall K R
Laboratory of Environmental Carcinogenesis and Mutagenesis, NIEHS, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA.
J Biol Chem. 1998 Oct 9;273(41):26662-9. doi: 10.1074/jbc.273.41.26662.
The role of specific mismatch repair (MMR) gene products was examined by observing several phenotypic end points in two MMR-deficient human endometrial carcinoma cell lines that were originally isolated from the same tumor. The first cell line, HEC-1-A, contains a nonsense mutation in the hPMS2 gene, which results in premature termination and a truncated hPMS2 protein. In addition, HEC-1-A cells carry a splice mutation in the hMSH6 gene and lack wild-type hMSH6 protein. The second cell line, HEC-1-B, possesses the same defective hMSH6 locus. However, HEC-1-B cells are heterozygous at the hPMS2 locus; that is, along with carrying the same nonsense mutation in hPMS2 as in HEC-1-A, HEC-1-B cells also contain a wild-type hPMS2 gene. Initial recognition of mismatches in DNA requires either the hMSH2/hMSH6 or hMSH2/hMSH3 heterodimer, with hPMS2 functioning downstream of damage recognition. Therefore, cells defective in hPMS2 should completely lack MMR (HEC-1-A), whereas cells mutant in hMSH6 only (HEC-1-B) can potentially repair damage via the hMSH2/hMSH3 heterodimer. The data presented here in HEC-1-B cells illustrate (i) the reduction of instability at microsatellite sequences, (ii) a significant decrease in frameshift mutation rate at HPRT, and (iii) the in vitro repair of looped substrates, relative to HEC-1-A cells, illustrating the repair of frameshift intermediates by hMSH2/hMSH3 heterodimer. Furthermore, the role of hMSH2/hMSH3 heterodimer in the repair of base:base mismatches is supported by observing the reduction in base substitution mutation rate at HPRT in HEC-1-B cells (hMSH6-defective but possessing wild-type hPMS2), as compared with HEC-1-A (hMSH6/hPMS2-defective) cells. These data support a critical role for hPMS2 in human MMR, while further defining the role of the hMSH2/hMSH3 heterodimer in maintaining genomic stability in the absence of a wild-type hMSH2/hMSH6 heterodimer.
通过观察最初从同一肿瘤中分离出的两种错配修复(MMR)缺陷型人子宫内膜癌细胞系中的几个表型终点,研究了特定错配修复(MMR)基因产物的作用。第一个细胞系HEC-1-A在hPMS2基因中存在一个无义突变,导致过早终止并产生截短的hPMS2蛋白。此外,HEC-1-A细胞在hMSH6基因中存在剪接突变,且缺乏野生型hMSH6蛋白。第二个细胞系HEC-1-B具有相同的缺陷型hMSH6基因座。然而,HEC-1-B细胞在hPMS2基因座处是杂合的;也就是说,与HEC-1-A中hPMS2存在相同的无义突变一样,HEC-1-B细胞也含有野生型hPMS2基因。DNA中错配的初始识别需要hMSH2/hMSH6或hMSH2/hMSH3异二聚体,hPMS2在损伤识别的下游发挥作用。因此,hPMS2缺陷的细胞应该完全缺乏错配修复(HEC-1-A),而仅hMSH6突变的细胞(HEC-1-B)可能通过hMSH2/hMSH3异二聚体修复损伤。本文展示的HEC-1-B细胞的数据表明:(i)微卫星序列处的不稳定性降低;(ii)次黄嘌呤磷酸核糖转移酶(HPRT)处的移码突变率显著降低;(iii)相对于HEC-1-A细胞,环状底物的体外修复,这表明hMSH2/hMSH3异二聚体可修复移码中间体。此外,与HEC-1-A(hMSH6/hPMS2缺陷)细胞相比,观察到HEC-1-B细胞(hMSH6缺陷但具有野生型hPMS2)中HPRT处的碱基替换突变率降低,这支持了hMSH2/hMSH3异二聚体在碱基:碱基错配修复中的作用。这些数据支持hPMS2在人类错配修复中的关键作用,同时进一步明确了在缺乏野生型hMSH2/hMSH6异二聚体的情况下,hMSH2/hMSH3异二聚体在维持基因组稳定性中的作用。